Adaptimmune nears second sarcoma approval as Phase II trial hits …
6 hours ago · Synovial sarcoma and MRCLS are rare and often aggressive cancers with limited treatment options. Synovial sarcoma is a soft tissue cancer that arises in the limbs, primarily affecting young adults.
Immunotherapy drug pembrolizumab improves outcomes for …
1 day ago · Across 20 institutions in the U.S., Canada, Australia and Italy, the researchers enrolled patients with stage 3, grade 2 or 3 soft tissue sarcoma of the extremities, including two subtypes ...
Clinical trial shows immunotherapy drug pembrolizumab improves …
2 days ago · Across 20 institutions in the U.S., Canada, Australia and Italy, the researchers enrolled patients with stage 3, grade 2 or 3 soft tissue sarcoma of the extremities, including two subtypes ...
FDA Approves New Treatment for Soft Tissue Sarcoma
The U.S. Food and Drug Administration (FDA) recently approved a new molecularly targeted therapeutic called olaratumab (Lartruvo) for treating certain patients with soft tissue sarcoma. Olaratumab is intended to be used in combination with …
First Cancer TCR Cell Therapy Approved by FDA - NCI
Aug 27, 2024 · On August 2, the Food and Drug Administration (FDA) approved a cellular therapy called afamitresgene autoleucel, or afami-cel (Tecelra), to treat some people with metastatic synovial sarcoma, a type of soft tissue sarcoma.
Immunotherapy before surgery leads to promising long-term …
Feb 13, 2024 · Patients with soft-tissue sarcoma treated with neoadjuvant, or pre-surgical, immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to Phase II trial results published today in Nature Cancer by researchers at The University of Texas MD Anderson Cancer Center.
FDA Approves First Engineered Cell Therapy for Treating Rare Sarcoma
Aug 2, 2024 · The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleuecel (Tecelra ®, also known as afami-cel) for the treatment of adults with a rare soft tissue cancer called synovial sarcoma.
Neoadjuvant Immunotherapy May Improve Long Term Survival in …
Feb 14, 2024 · Patients with soft-tissue sarcoma treated with neoadjuvant immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to phase II trial results published by Roland et al in Nature Cancer.
FDA approves first treatment option specifically for patients …
FDA granted accelerated approval to Tazverik (tazemetostat) for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not...
Immunotherapy Drug Pembrolizumab Improves Outcomes for …
Soft tissue sarcoma of the extremity is a group of tumors that originate in the muscles, tendons, fat, blood vessels or nerves of the legs and arms. About half of patients with large, high-grade sarcomas develop incurable metastases, so intervention before signs of metastatic disease is essential, according to Mowery.
- Some results have been removed